Does the media refer more to BNTX or ORKA?

In the previous week, Oruka Therapeutics had 11 more articles in the media than BioNTech. MarketBeat recorded 22 mentions for Oruka Therapeutics and 11 mentions for BioNTech. BioNTech's average media sentiment score of 0.58 beat Oruka Therapeutics' score of 0.49 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 5 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to UTHR or ORKA?

In the previous week, Oruka Therapeutics had 5 more articles in the media than United Therapeutics. MarketBeat recorded 22 mentions for Oruka Therapeutics and 17 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.65 beat Oruka Therapeutics' score of 0.49 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 6 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 5 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MRNA or ORKA?

In the previous week, Oruka Therapeutics had 7 more articles in the media than Moderna. MarketBeat recorded 22 mentions for Oruka Therapeutics and 15 mentions for Moderna. Oruka Therapeutics' average media sentiment score of 0.49 beat Moderna's score of 0.35 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 3 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Oruka Therapeutics 5 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer GMAB or ORKA?

In the previous week, Oruka Therapeutics had 13 more articles in the media than Genmab A/S. MarketBeat recorded 22 mentions for Oruka Therapeutics and 9 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.51 beat Oruka Therapeutics' score of 0.49 indicating that Genmab A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 5 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BBIO or ORKA?

In the previous week, BridgeBio Pharma had 17 more articles in the media than Oruka Therapeutics. MarketBeat recorded 39 mentions for BridgeBio Pharma and 22 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 0.49 beat BridgeBio Pharma's score of 0.47 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 8 Very Positive mention(s) 7 Positive mention(s) 12 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Oruka Therapeutics 5 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Oruka Therapeutics (ORKA) Competitors

$106.43 -1.69 (-1.56%)

As of 09:32 AM Eastern

Compare

ORKA vs. BNTX, UTHR, MRNA, GMAB, and BBIO

Should you buy Oruka Therapeutics stock or one of its competitors? Oruka Therapeutics's main competitors and comparable companies include BioNTech (BNTX), United Therapeutics (UTHR), Moderna (MRNA), Genmab A/S (GMAB), and BridgeBio Pharma (BBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oruka Therapeutics compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

In the previous week, Oruka Therapeutics had 11 more articles in the media than BioNTech. MarketBeat recorded 22 mentions for Oruka Therapeutics and 11 mentions for BioNTech. BioNTech's average media sentiment score of 0.58 beat Oruka Therapeutics' score of 0.49 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	5 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oruka Therapeutics has lower revenue, but higher earnings than BioNTech. Oruka Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.18	-$1.29B	-$7.83	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

BioNTech has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, indicating that its share price is 134% less volatile than the broader market.

Oruka Therapeutics has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Oruka Therapeutics	N/A	-28.80%	-27.54%

BioNTech presently has a consensus price target of $127.81, indicating a potential upside of 38.75%. Oruka Therapeutics has a consensus price target of $134.30, indicating a potential upside of 24.21%. Given BioNTech's higher probable upside, analysts clearly believe BioNTech is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

15.5% of BioNTech shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 23.5% of Oruka Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

BioNTech beats Oruka Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Oruka Therapeutics compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

United Therapeutics has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, suggesting that its stock price is 134% less volatile than the broader market.

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

United Therapeutics presently has a consensus price target of $646.00, indicating a potential upside of 28.87%. Oruka Therapeutics has a consensus price target of $134.30, indicating a potential upside of 24.21%. Given United Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe United Therapeutics is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

United Therapeutics has a net margin of 41.56% compared to Oruka Therapeutics' net margin of 0.00%. United Therapeutics' return on equity of 20.18% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Oruka Therapeutics	N/A	-28.80%	-27.54%

United Therapeutics has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.15B	6.82	$1.33B	$27.95	17.93
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

In the previous week, Oruka Therapeutics had 5 more articles in the media than United Therapeutics. MarketBeat recorded 22 mentions for Oruka Therapeutics and 17 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.65 beat Oruka Therapeutics' score of 0.49 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	6 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	5 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

United Therapeutics beats Oruka Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Oruka Therapeutics compare to Moderna?

Moderna (NASDAQ:MRNA) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

75.3% of Moderna shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 23.5% of Oruka Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Moderna presently has a consensus target price of $42.13, indicating a potential downside of 33.80%. Oruka Therapeutics has a consensus target price of $134.30, indicating a potential upside of 24.21%. Given Oruka Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Oruka Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	1.88
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Oruka Therapeutics has lower revenue, but higher earnings than Moderna. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	13.07	-$2.82B	-$7.99	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

Oruka Therapeutics has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Oruka Therapeutics	N/A	-28.80%	-27.54%

Moderna has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, indicating that its stock price is 134% less volatile than the broader market.

In the previous week, Oruka Therapeutics had 7 more articles in the media than Moderna. MarketBeat recorded 22 mentions for Oruka Therapeutics and 15 mentions for Moderna. Oruka Therapeutics' average media sentiment score of 0.49 beat Moderna's score of 0.35 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	3 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oruka Therapeutics	5 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Oruka Therapeutics beats Moderna on 9 of the 15 factors compared between the two stocks.

How does Oruka Therapeutics compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Genmab A/S has a net margin of 19.08% compared to Oruka Therapeutics' net margin of 0.00%. Genmab A/S's return on equity of 14.89% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
Oruka Therapeutics	N/A	-28.80%	-27.54%

Genmab A/S has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, indicating that its stock price is 134% less volatile than the broader market.

Genmab A/S presently has a consensus target price of $39.50, suggesting a potential upside of 26.04%. Oruka Therapeutics has a consensus target price of $134.30, suggesting a potential upside of 24.21%. Given Genmab A/S's stronger consensus rating and higher possible upside, research analysts clearly believe Genmab A/S is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Genmab A/S has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	5.25	$963M	$1.27	24.68
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

In the previous week, Oruka Therapeutics had 13 more articles in the media than Genmab A/S. MarketBeat recorded 22 mentions for Oruka Therapeutics and 9 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.51 beat Oruka Therapeutics' score of 0.49 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	5 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Genmab A/S beats Oruka Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Oruka Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Oruka Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-62.80%
Oruka Therapeutics	N/A	-28.80%	-27.54%

BridgeBio Pharma presently has a consensus price target of $100.79, suggesting a potential upside of 24.11%. Oruka Therapeutics has a consensus price target of $134.30, suggesting a potential upside of 24.21%. Given Oruka Therapeutics' higher possible upside, analysts clearly believe Oruka Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

BridgeBio Pharma has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, indicating that its share price is 134% less volatile than the broader market.

In the previous week, BridgeBio Pharma had 17 more articles in the media than Oruka Therapeutics. MarketBeat recorded 39 mentions for BridgeBio Pharma and 22 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 0.49 beat BridgeBio Pharma's score of 0.47 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	8 Very Positive mention(s)	7 Positive mention(s)	12 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oruka Therapeutics	5 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Oruka Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. Oruka Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	31.62	-$724.93M	-$3.57	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

Summary

BridgeBio Pharma beats Oruka Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Oruka Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORKA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORKA vs. The Competition

Export

Metric	Oruka Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.11B	$3.75B	$7.07B	$13.00B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-53.26	10.24	269.63	25.21
Price / Sales	N/A	1,291.29	596.70	99.90
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	11.16	17.68	13.11	6.24
Net Income	-$105.43M	-$13.30M	$3.45B	$347.70M
7 Day Performance	9.41%	0.66%	0.77%	0.87%
1 Month Performance	23.61%	0.51%	1.44%	0.90%
1 Year Performance	620.80%	54.56%	67.07%	20.13%

Oruka Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORKA Oruka Therapeutics	3.3031 of 5 stars	$108.12 +0.7%	$134.30 +24.2%	+605.3%	$7.11B	N/A	N/A	N/A	News Coverage Earnings Report Analyst Forecast
BNTX BioNTech	3.3461 of 5 stars	$93.67 +2.7%	$127.81 +36.4%	-18.3%	$23.06B	$3.25B	N/A	7,807
UTHR United Therapeutics	4.3665 of 5 stars	$538.84 +1.1%	$646.00 +19.9%	+61.8%	$22.62B	$3.15B	19.28	1,400	Insider Trade Analyst Revision High Trading Volume
MRNA Moderna	1.351 of 5 stars	$59.17 +9.9%	$42.13 -28.8%	+136.7%	$21.50B	$1.94B	N/A	4,700
GMAB Genmab A/S	4.4086 of 5 stars	$31.25 +4.8%	$39.50 +26.4%	+38.2%	$18.60B	$3.72B	24.61	3,029	Positive News Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORKA) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oruka Therapeutics (ORKA) Competitors

ORKA vs. BNTX, UTHR, MRNA, GMAB, and BBIO

How does Oruka Therapeutics compare to BioNTech?

Summary

How does Oruka Therapeutics compare to United Therapeutics?

Summary

How does Oruka Therapeutics compare to Moderna?

Summary

How does Oruka Therapeutics compare to Genmab A/S?

Summary

How does Oruka Therapeutics compare to BridgeBio Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORKA vs. The Competition

Oruka Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oruka Therapeutics (ORKA) Competitors

ORKA vs. BNTX, UTHR, MRNA, GMAB, and BBIO

How does Oruka Therapeutics compare to BioNTech?

Does the media refer more to BNTX or ORKA?

Which has preferable valuation & earnings, BNTX or ORKA?

Which has more volatility and risk, BNTX or ORKA?

Is BNTX or ORKA more profitable?

Do analysts recommend BNTX or ORKA?

Do institutionals & insiders believe in BNTX or ORKA?

Summary

How does Oruka Therapeutics compare to United Therapeutics?

Which has more volatility and risk, UTHR or ORKA?

Do insiders and institutionals have more ownership in UTHR or ORKA?

Do analysts rate UTHR or ORKA?

Is UTHR or ORKA more profitable?

Which has stronger earnings and valuation, UTHR or ORKA?

Does the media refer more to UTHR or ORKA?

Summary

How does Oruka Therapeutics compare to Moderna?

Do insiders & institutionals believe in MRNA or ORKA?

Do analysts rate MRNA or ORKA?

Which has preferable valuation and earnings, MRNA or ORKA?

Is MRNA or ORKA more profitable?

Which has more volatility & risk, MRNA or ORKA?

Does the media prefer MRNA or ORKA?

Summary

How does Oruka Therapeutics compare to Genmab A/S?

Do insiders & institutionals hold more shares of GMAB or ORKA?

Is GMAB or ORKA more profitable?

Which has more volatility & risk, GMAB or ORKA?

Do analysts rate GMAB or ORKA?

Which has stronger valuation & earnings, GMAB or ORKA?

Does the media prefer GMAB or ORKA?

Summary

How does Oruka Therapeutics compare to BridgeBio Pharma?

Is BBIO or ORKA more profitable?

Do analysts rate BBIO or ORKA?

Which has more risk & volatility, BBIO or ORKA?

Does the media favor BBIO or ORKA?

Do insiders & institutionals hold more shares of BBIO or ORKA?

Which has higher earnings & valuation, BBIO or ORKA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORKA vs. The Competition

Oruka Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools